deltatrials
Completed PHASE1/PHASE2 NCT00596648

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer

Sponsor: Exelixis

Conditions Carcinoma, Non-Small-Cell Lung
Interventions XL184 erlotinib
Updated 8 times since 2017 Last updated: Dec 19, 2025 Started: Feb 12, 2008 Primary completion: Aug 2, 2012 Completion: Aug 2, 2012

Listed as NCT00596648, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by Exelixis, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Exelixis
Data source: Exelixis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anchorage, United States, Berkeley Heights, United States, Boston, United States, Chicago, United States, Cleveland, United States, Houston, United States, New Haven, United States, Palo Alto, United States, Sacramento, United States, Saint Louis Park, United States and 2 more location s